Peg-interferon lambda treatment induces robust innate and adaptive immunity in chronic hepatitis B patients

Frontiers in Immunology

Volumn 8, Issue MAY, 2017, Pages

  Phillips, Sandra ^a,b   Mistry, Sameer ^a,b   Riva, Antonio ^a,b   Cooksley, Helen ^a,b   Hadzhiolova Lebeau, Tanya ^c   Plavova, Slava ^c   Katzarov, Krum ^c   Simonova, Marieta ^c   Zeuzem, Stephan ^d   Woffendin, Clive ^e   Chen, Pei Jer ^f   Peng, Cheng Yuan ^g   Chang, Ting Tsung ^h   Lueth, Stefan ⁱ   Knegt, Robert De ^j   Choi, Moon Seok ^k   Wedemeyer, Heiner ^l   Dao, Michael ^m   Kim, Chang Wook ⁿ   Chu, Heng Chen ^o   Wind Rotolo, Megan ^p   Williams, Roger ^a,b   Cooney, Elizabeth ^f   Chokshi, Shilpa ^a,b   more..

^a INSTITUTE OF HEPATOLOGY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c MILITARY MEDICAL ACADEMY   (Bulgaria)

^d UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^e Oregon Clinic   (United States)

^f NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^h NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

ⁱ UNIVERSITY OF HAMBURG   (Germany)

^j ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^k Sungkyunkwan University   (South Korea)

^l HANNOVER MEDICAL SCHOOL   (Germany)

^m Precision Diagnostic Laboratory   (United States)

ⁿ The Catholic University of Korea   (South Korea)

^o TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^p BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Direct antiviral; Hepatitis B; Immunity; In vivo; Peg interferon lambda

Indexed keywords

ALPHA1 INTERFERON; CD16 ANTIGEN; CD56 ANTIGEN; ENTECAVIR; GAMMA INTERFERON; GRANZYME B; HEPATITIS B SURFACE ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 12P70; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PEGINTERFERON LAMBDA; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADAPTIVE IMMUNITY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANALYSIS OF VARIANCE; ARTICLE; CELL DIFFERENTIATION ASSAY; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CONTROLLED STUDY; DEGRANULATION ASSAY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; HUMAN; IMMUNE RESPONSE; IMMUNOSURVEILLANCE; INNATE IMMUNITY; MALE; MIDDLE AGED; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

EID: 85020018105     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00621     Document Type: Article

References (79)

1. Levy DE, Garcia-Sastre A. The virus battles: IFN induction of the antiviral state and mechanisms of viral evasion. Cytokine Growth Factor Rev (2001) 12:143-56. doi: 10.1016/S1359-6101(00)00027-7
2. Huber JP, Farrar JD. Regulation of effector and memory T-cell functions by type I interferon. Immunology (2011) 132:466-74. doi:10.1111/j.1365-2567.2011.03412.x
3. Levy DE, Marie IJ, Durbin JE. Induction and function of type I and III interferon in response to viral infection. Curr Opin Virol (2011) 1:476-86. doi:10.1016/j.coviro.2011.11.001
4. Heim MH. Interferons and hepatitis C virus. Swiss Med Wkly (2012) 142:w13586. doi:10.4414/smw.2012.13586
5. Gibbert K, Schlaak JF, Yang D, Dittmer U. IFN-alpha subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol (2013) 168:1048-58. doi:10.1111/bph.12010
6. Pagliaccetti NE, Chu EN, Bolen CR, Kleinstein SH, Robek MD. Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities. Virology (2010) 401:197-206. doi:10.1016/j.virol.2010.02.022
7. EASL. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol (2012) 57:167-85. doi:10.1016/j.jhep.2012.02.010
8. Konerman MA, Lok AS. Interferon treatment for hepatitis B. Clin Liver Dis (2016) 20:645-65. doi:10.1016/j.cld.2016.06.002
9. Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattenberg JM, Galle PR, et al. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol (2012) 54:93-5. doi:10.1016/j.jcv.2012.01.024
10. Boglione L, D'avolio A, Cariti G, Milia MG, Simiele M, De NA, et al. Sequential therapy with entecavir and PEG-INF in patients affected by chronic hepatitis B and high levels of HBV-DNA with non-D genotypes. J Viral Hepat (2013) 20:e11-9. doi:10.1111/jvh.12018
11. Ouzan D, Penaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol (2013) 58:713-7. doi:10.1016/j.jcv.2013.09.020
12. Penna A, Laccabue D, Libri I, Giuberti T, Schivazappa S, Alfieri A, et al. Peginterferon-alpha does not improve early peripheral blood HBV-specific T-cell responses in HBeAg-negative chronic hepatitis. J Hepatol (2012) 56:1239-46. doi:10.1016/j.jhep.2011.12.032
13. Micco L, Peppa D, Loggi E, Schurich A, Jefferson L, Cursaro C, et al. Differential boosting of innate and adaptive antiviral responses during pegylated-interferon-alpha therapy of chronic hepatitis B. J Hepatol (2013) 58:225-33. doi:10.1016/j.jhep.2012.09.029
14. Tan AT, Hoang LT, Chin D, Rasmussen E, Lopatin U, Hart S, et al. Reduction of HBV replication prolongs the early immunological response to IFNalpha therapy. J Hepatol (2014) 60:54-61. doi:10.1016/j.jhep.2013.08.020
15. Stelma F, De NA, Tempelmans Plat-Sinnige MJ, Jansen L, Takkenberg RB, Reesink HW, et al. Natural killer cell characteristics in patients with chronic hepatitis B virus (HBV) infection are associated with HBV surface antigen clearance after combination treatment with pegylated interferon alfa-2a and adefovir. J Infect Dis (2015) 212:1042-51. doi:10.1093/infdis/jiv180
16. Dai J, Megjugorac NJ, Gallagher GE, Yu RY, Gallagher G. IFN-lambda1 (IL-29) inhibits GATA3 expression and suppresses Th2 responses in human naive and memory T cells. Blood (2009) 113:5829-38. doi:10.1182/blood-2008-09-179507
17. Megjugorac NJ, Gallagher GE, Gallagher G. Modulation of human plasmacytoid DC function by IFN-lambda1 (IL-29). J Leukoc Biol (2009) 86:1359-63. doi:10.1189/jlb.0509347
18. Witte K, Gruetz G, Volk HD, Looman AC, Asadullah K, Sterry W, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes Immun (2009) 10:702-14. doi:10.1038/gene.2009.72
19. De Groen RA, Boltjes A, Hou J, Liu BS, Mcphee F, Friborg J, et al. IFN-lambda-mediated IL-12 production in macrophages induces IFN-gamma production in human NK cells. Eur J Immunol (2015) 45(1):250-9. doi:10.1002/eji.201444903
20. Kelly A, Robinson MW, Roche G, Biron CA, O'farrelly C, Ryan EJ. Immune cell profiling of IFN-lambda response shows pDCs express highest level of IFN-lambdaR1 and are directly responsive via the JAK-STAT pathway. J Interferon Cytokine Res (2016) 36:671-80. doi:10.1089/jir.2015.0169
21. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology (2006) 44:896-906. doi:10.1002/hep.21312
22. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, Macdonald MR, et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology (2006) 131:1887-98. doi:10.1053/j.gastro.2006.09.052
23. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog (2008) 4:e1000017. doi:10.1371/journal.ppat.1000017
24. Liu BS, Janssen HL, Boonstra A. IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. Blood (2011) 117:2385-95. doi:10.1182/blood-2010-07-298976
25. Numasaki M, Tagawa M, Iwata F, Suzuki T, Nakamura A, Okada M, et al. IL-28 elicits antitumor responses against murine fibrosarcoma. J Immunol (2007) 178:5086-98. doi:10.4049/jimmunol.178.8.5086
26. Dring MM, Morrison MH, Mcsharry BP, Guinan KJ, Hagan R; Irish HCV Research Consortium, et al. Innate immune genes synergize to predict increased risk of chronic disease in hepatitis C virus infection. Proc Natl Acad Sci U S A (2011) 108:5736-41. doi:10.1073/pnas.1016358108
27. Morrison MH, Keane C, Quinn LM, Kelly A, O'farrelly C, Bergin C, et al. IFNL cytokines do not modulate human or murine NK cell functions. Hum Immunol (2014) 75:996-1000. doi:10.1016/j.humimm.2014.06.016
28. Sato A, Ohtsuki M, Hata M, Kobayashi E, Murakami T. Antitumor activity of IFN-lambda in murine tumor models. J Immunol (2006) 176:7686-94. doi:10.4049/jimmunol.176.12.7686
29. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M, et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun (2007) 8:254-61. doi:10.1038/sj.gene.6364348
30. Koltsida O, Hausding M, Stavropoulos A, Koch S, Tzelepis G, Ubel C, et al. IL-28A (IFN-lambda2) modulates lung DC function to promote Th1 immune skewing and suppress allergic airway disease. EMBO Mol Med (2011) 3:348-61. doi:10.1002/emmm.201100142
31. Boni C, Fisicaro P, Valdatta C, Amadei B, Di VP, Giuberti T, et al. Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection. J Virol (2007) 81:4215-25. doi:10.1128/JVI.02844-06
32. Lau GK, Cooksley H, Ribeiro RM, Powers KA, Shudo E, Bowden S, et al. Impact of early viral kinetics on T-cell reactivity during antiviral therapy in chronic hepatitis B. Antivir Ther (2007) 12:705-18.
33. Cooksley H, Chokshi S, Maayan Y, Wedemeyer H, Andreone P, Gilson R, et al. Hepatitis B virus e antigen loss during adefovir dipivoxil therapy is associated with enhanced virus-specific CD4+ T-cell reactivity. Antimicrob Agents Chemother (2008) 52:312-20. doi:10.1128/AAC.00467-07
34. Evans A, Riva A, Cooksley H, Phillips S, Puranik S, Nathwani A, et al. Programmed death 1 expression during antiviral treatment of chronic hepatitis B: impact of hepatitis B e-antigen seroconversion. Hepatology (2008) 48:759-69. doi:10.1002/hep.22419
35. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, et al. Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B. Gastroenterology (2010) 138:682-93, 693.e1-4. doi:10.1053/j.gastro.2009.09.052
36. Tjwa ET, Van Oord GW, Hegmans JP, Janssen HL, Woltman AM. Viral load reduction improves activation and function of natural killer cells in patients with chronic hepatitis B. J Hepatol (2011) 54:209-18. doi:10.1016/j.jhep.2010.07.009
37. Chokshi S, Cooksley H, Riva A, Phillips S, Williams R, Gaggar A, et al. Identification of serum cytokine profiles associated with HBeAg seroconversion following antiviral treatment interruption. Viral Immunol (2014) 27:235-44. doi:10.1089/vim.2014.0022
38. Rehermann B. Natural killer cells in viral hepatitis. Cell Mol Gastroenterol Hepatol (2015) 1:578-88. doi:10.1016/j.jcmgh.2015.09.004
39. Penna A, Artini M, Cavalli A, Levrero M, Bertoletti A, Pilli M, et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest (1996) 98:1185-94. doi:10.1172/JCI118902
40. Lau GK, Liang R, Chiu EK, Lee CK, Lam SK. Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study. Bone Marrow Transplant (1997) 19:795-9. doi:10.1038/sj.bmt.1700744
41. Lau GK, Lok AS, Liang RH, Lai CL, Chiu EK, Lau YL, et al. Clearance of hepatitis B surface antigen after bone marrow transplantation: role of adoptive immunity transfer. Hepatology (1997) 25:1497-501. doi:10.1002/hep.510250631
42. Lau GK, Liang R, Lee CK, Yuen ST, Hou J, Lim WL, et al. Clearance of persistent hepatitis B virus infection in Chinese bone marrow transplant recipients whose donors were anti-hepatitis B core- and anti-hepatitis B surface antibody-positive. J Infect Dis (1998) 178:1585-91. doi:10.1086/314497
43. Webster GJ, Reignat S, Maini MK, Whalley SA, Ogg GS, King A, et al. Incubation phase of acute hepatitis B in man: dynamic of cellular immune mechanisms. Hepatology (2000) 32:1117-24. doi:10.1053/jhep.2000.19324
44. Riva A, Laird M, Casrouge A, Ambrozaitis A, Williams R, Naoumov NV, et al. Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection. Hepatology (2014) 60(2):487-96. doi:10.1002/hep.27139
45. Markwick LJ, Riva A, Ryan JM, Cooksley H, Palma E, Tranah TH, et al. Blockade of PD1 and TIM3 restores innate and adaptive immunity in patients with acute alcoholic hepatitis. Gastroenterology (2015) 148:590-602. doi:10.1053/j.gastro.2014.11.041
46. Chan HL, Ahn SH, Chang TT, Peng CY, Wong D, Coffin CS, et al. Peginterferon lambda for the treatment of HBeAg-positive chronic hepatitis B: a randomized phase 2b study (LIRA-B). J Hepatol (2016) 64:1011-9. doi:10.1016/j.jhep.2015.12.018
47. Chang TT, Gish RG, De MR, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med (2006) 354:1001-10. doi:10.1056/NEJMoa051285
48. Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, et al. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: a randomized international study of entecavir versus adefovir. Hepatology (2009) 49:72-9. doi:10.1002/hep.22658
49. Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut (2012) 61(Suppl 1):i18-24. doi:10.1136/gutjnl-2012-302085
50. Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterol (2013) 48:13-21. doi:10.1007/s00535-012-0668-y
51. Honer Zu SC, Cornberg M. The role of HBsAg levels in the current management of chronic HBV infection. Ann Gastroenterol (2014) 27:105-12.
52. Van Campenhout MJ, Janssen HL. How to achieve immune control in chronic hepatitis B? Hepatol Int (2015) 9:9-16. doi:10.1007/s12072-014-9571-3
53. Dunn C, Brunetto M, Reynolds G, Christophides T, Kennedy PT, Lampertico P, et al. Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage. J Exp Med (2007) 204:667-80. doi:10.1084/jem.20061287
54. Oliviero B, Varchetta S, Paudice E, Michelone G, Zaramella M, Mavilio D, et al. Natural killer cell functional dichotomy in chronic hepatitis B and chronic hepatitis C virus infections. Gastroenterology (2009) 137:1151-60, 1160.e1-7. doi:10.1053/j.gastro.2009.05.047
55. Sun C, Fu B, Gao Y, Liao X, Sun R, Tian Z, et al. TGF-beta1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence. PLoS Pathog (2012) 8:e1002594. doi:10.1371/journal.ppat.1002594
56. Gish RG, Given BD, Lai CL, Locarnini SA, Lau JY, Lewis DL, et al. Chronic hepatitis B: virology, natural history, current management and a glimpse at future opportunities. Antiviral Res (2015) 121:47-58. doi:10.1016/j.antiviral.2015.06.008
57. Webster GJ, Reignat S, Brown D, Ogg GS, Jones L, Seneviratne SL, et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol (2004) 78:5707-19. doi:10.1128/JVI.78.11.5707-5719.2004
58. Perussia B. The cytokine profile of resting and activated NK cells. Methods (1996) 9:370-8. doi:10.1006/meth.1996.0042
59. Moretta A, Marcenaro E, Parolini S, Ferlazzo G, Moretta L. NK cells at the interface between innate and adaptive immunity. Cell Death Differ (2008) 15:226-33. doi:10.1038/sj.cdd.4402170
60. Strowig T, Brilot F, Munz C. Noncytotoxic functions of NK cells: direct pathogen restriction and assistance to adaptive immunity. J Immunol (2008) 180:7785-91. doi:10.4049/jimmunol.180.12.7785
61. Peppa D, Micco L, Javaid A, Kennedy PT, Schurich A, Dunn C, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathog (2010) 6:e1001227. doi:10.1371/journal.ppat.1001227
62. Maini MK, Boni C, Lee CK, Larrubia JR, Reignat S, Ogg GS, et al. The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection. J Exp Med (2000) 191:1269-80. doi:10.1084/jem.191.8.1269
63. Vanderlugt CL, Miller SD. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat Rev Immunol (2002) 2:85-95. doi:10.1038/nri724
64. You J, Sriplung H, Geater A, Chongsuvivatwong V, Zhuang L, Li YL, et al. Impact of viral replication inhibition by entecavir on peripheral T lymphocyte subpopulations in chronic hepatitis B patients. BMC Infect Dis (2008) 8:123. doi:10.1186/1471-2334-8-123
65. Boni C, Laccabue D, Lampertico P, Giuberti T, Vigano M, Schivazappa S, et al. Restored function of HBV-specific T cells after long-term effective therapy with nucleos(t)ide analogues. Gastroenterology (2012) 143:963-73. doi:10.1053/j.gastro.2012.07.014
66. Phillips S, Chokshi S, Riva A, Evans A, Williams R, Naoumov NV. CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions. J Immunol (2010) 184:287-95. doi:10.4049/jimmunol.0902761
67. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol (2006) 80:4501-9. doi:10.1128/JVI.80.9.4501-4509.2006
68. Ye B, Liu X, Li X, Kong H, Tian L, Chen Y. T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance. Cell Death Dis (2015) 6:e1694. doi:10.1038/cddis.2015.42
69. Lu J-J, Chen E-Q, Yang J-H, Zhou T-Y, Liu L, Tang H. A mutation in the interferon regulatory element of HBV may influence the response of interferon treatment in chronic hepatitis B patients. Virol J (2012) 9:10. doi:10.1186/1743-422X-9-10
70. Chen J, Wu M, Wang F, Zhang W, Wang W, Zhang X, et al. Hepatitis B virus spliced variants are associated with an impaired response to interferon therapy. Sci Rep (2015) 5:16459. doi:10.1038/srep16459
71. Wu HL, Hsiao TH, Chen PJ, Wong SH, Kao JH, Chen DS, et al. Liver gene expression profiles correlate with virus infection and response to interferon therapy in chronic hepatitis B patients. Sci Rep (2016) 6:31349. doi:10.1038/srep31349
72. Du L-Y, Cui Y-L, Chen E-Q, Cheng X, Liu L, Tang H. Correlation between the suppressor of cytokine signaling-1 and 3 and hepatitis B virus: possible roles in the resistance to interferon treatment. Virol J (2014) 11:51. doi:10.1186/1743-422X-11-51
73. Wei H, Wang S, Chen Q, Chen Y, Chi X, Zhang L, et al. Suppression of interferon lambda signaling by SOCS-1 results in their excessive production during influenza virus infection. PLoS Pathog (2014) 10:e1003845. doi:10.1371/journal.ppat.1003845
74. Barnes E, Gelderblom HC, Humphreys I, Semmo N, Reesink HW, Beld MG, et al. Cellular immune responses during high-dose interferon-alpha induction therapy for hepatitis C virus infection. J Infect Dis (2009) 199:819-28. doi:10.1086/597072
75. Marshall HD, Urban SL, Welsh RM. Virus-induced transient immune suppression and the inhibition of T cell proliferation by type I interferon. J Virol (2011) 85:5929-39. doi:10.1128/JVI.02516-10
76. O'Brien M, Manches O, Sabado RL, Baranda SJ, Wang Y, Marie I, et al. Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-alpha-producing and partially matured phenotype. J Clin Invest (2011) 121:1088-101. doi:10.1172/JCI44960
77. Pinto AK, Daffis S, Brien JD, Gainey MD, Yokoyama WM, Sheehan KC, et al. A temporal role of type I interferon signaling in CD8+ T cell maturation during acute West Nile virus infection. PLoS Pathog (2011) 7:e1002407. doi:10.1371/journal.ppat.1002407
78. Brunetto MR, Moriconi F, Bonino F, Lau GK, Farci P, Yurdaydin C, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology (2009) 49:1141-50. doi:10.1002/hep.22760
79. Chan HL, Wong VW, Wong GL, Tse CH, Chan HY, Sung JJ. A longitudinal study on the natural history of serum hepatitis B surface antigen changes in chronic hepatitis B. Hepatology (2010) 52:1232-41. doi:10.1002/hep.23803